JAZZ News and Press, Jazz Pharmaceuticals plc From 08/04/21

After the market closed on Tuesday, Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021. Jazz also said that it plans to expand the use of GW Pharmaceutical’s drug ...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2021 Q2 earnings call. For further details see: Jazz Pharmaceuticals plc 2021 Q2 - Results - Earnings Call Presentation

Image source: The Motley Fool. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q2 2021 Earnings Call Aug 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Jazz Pharmaceuticals PLC (JAZZ) Q2 2021 Earnings Call Transcript

Jazz Pharmaceuticals PLC (JAZZ) Q2 2021 Earnings Conference Call August 03, 2021 4:30 PM ET Company Participants Andrea Flynn – Investor Relations Bruce Cozadd – Chairman and Chief Executive Officer Renee Gala – Executive Vice President and Chief Financial Officer Dan Swi...

It’s time for your Daily Hit of cannabis financial news for July 3, 2021. On The Site Hemp Prices July 2021 saw record-setting temperatures in parts of the country, alarming spikes in Delta variant Covid infections, and large numbers of Americans retur...

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter results that beat Wall Street estimates, powered by the strength in its Oxybate business. Quarterly revenue increased 34% to $751.8M, beating analysts' average estimate by $14.5M. The company also reiterated its FY forecasts...

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q2 Non-GAAP EPS of $3.90 beats by $0.45; GAAP EPS of -$6.11 misses by $2.81. Revenue of $751.8M (+33.7% Y/Y) beats by $14.5M. Re-affirms prior revenue guidance of $3.02B-$3.18B vs. $3.11B consensus. Re-affirms prior Non-GAAP EPS of $13.40-$14.70 vs. $14.42 ...

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results Closed GW Pharmaceuticals plc Acquisition, Creating an Innovative, High-Growth, Global Biopharma Leader 41% of Net Product Sales from Recently Launched or Acquired Products Strong Xywav™ Adoption...

In February, biotech company Jazz Pharmaceuticals (NASDAQ: JAZZ) made some noise when it announced it would acquire GW Pharmaceuticals, a drugmaker specializing in developing cannabidiol (CBD)-derived medicines. The cash-and-stock transaction, which closed in May, was valued at $7.2...

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...